Home Up Feedback Contents Search Sell your Prod. Meet us News           

 
Home • Up

C013

 

Home

GENTAUR

+32 1658 9045

or

0032 (0)16 41 44 07

+32 1650 9045

[email protected]

Av. de l' Armée 68

B-1040 Brussels

BELGIUM

France

tel 01 43 25 01 50

fax01 43 25 01 60

9, rue Lagrange

75005 Paris

Italia

tel 02 36 00 65 93

fax 02 36 00 65 94

20135 Milano

Deutschland

tel +32 1658 9045

fax +32 1650 9045

Polska

Tel 058 710 33 44

Fax 00 32 16 50 90 45

ul. Grunwaldzka 88A/2

81-771 Sopot

日本

tel +81 78 386 0860

fax +81 78 306 0296

Minaatojimaminami-manchi

Chuo-ku, Kobe

065-0047

Österreich
+43720880899

Canada Montreal
+15149077481

Česká republika Praha
+420246019719

Danmark
+4569918806

Finland Helsset
+358942419041

Ελλάς Αθήνα
+302111768494

Magyarország Budapest
+3619980547

Ireland Dublin
+35316526556

Luxembourg
+35220880274

Nederland
+31208080893

Norge Oslo
+4721031366

Polska Warszawa
+48223988221

Sverige Stockholm
+46852503438

Schweiz Züri
+41435006251

US New York
+17185132983

Other Countries
0032 (0)16 41 44 07


 

 

 

 

 

Recombinant Human Interleukin-2 (IL2)
(Cat. No.: C013)


Background:
       
In vitro studies performed on human cell lines demonstrate the immunoregulatory properties of IL-2 including: 1) enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human IL-2 dependent edll lines; 2) enhancement of lymphocyte cytotoxicity; 3) induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; 4) dnduction of interferon-gamma production.

Description:
       
Recombinant Human interleukin-2 is a highly purified protein with a molecular weight of approximately 15,300 Daltons. The chemical name is des-alanyl-1, serine-125 human interleukin-2. It is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human IL-2. This recombinant form differs from native interleukin-2 in following ways: 1) it is not glycosylated; 2) the molecule has no N-terminal alanine; 3) the molecule has serine substituted for cysteine at amino acid position 125; 4) the aggregation state of molecule is likely to be different from that of native IL-2.

Quality Control:
        Biological activity:
The ED50 as determined by the dose-dependant stimulation of murine CTLL-2 cells is less then 0.1 ng/ml, corresponding to a Specific Activity of 1.0 x 107 IU/ mg.
        Purity: Greater than 95% as determined by
                    (a) Analysis by SEC-HPLC.
                    (b) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.
        Isoelectric Point: the main zone between 6.5~7.5 analysis by IEF.
        Amino-Acid Sequence: The sequence of the first fifteen N-terminal amino acids was determined and was found to be Met-Ala-Pro-Thr-Ser-Ser-Ser-Thr-Lys-Lys-Thr-Gln-Leu- Gln-Leu-Glu.
        Endotoxin: Less than 0.1ng/µg (0.1IEU/µg) determined by LAL test.

Formulation: The protein (1.1mg/ml) was lyophilized after extensive dialysis against 0.17mg sodium monobasic and 0.89mg dibasic sodium phosphate buffer to a pH=7.5.

Storage: Lyophilized rHuIL-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18oC. Upon reconstitution rHuIL-2 should be stored at 4oC between 2-7 days and for future use below -18oC. For long-term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
        Please avoid freeze-thaw cycles.

Reconstitution: It is recommended to reconstitute the lyophilized rHuIL-2 in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.

 

 


 
*NOTE: ALL PRODUCTS ARE FOR RESEARCH USE ONLY

 

Copyright © 2002 GENTAUR Molecular Products
Last modified: 05/29/09